Literature DB >> 6226471

Clinical pharmacokinetics of fentanyl and its newer derivatives.

L E Mather.   

Abstract

Fentanyl, a synthetic opiate with a (clinical) potency of 50 to 100 times that of morphine, was introduced into clinical practice in the early 1960s. Usually administered by single intravenous doses, it developed a reputation for having a short duration of action and it was assumed that this was a consequence of rapid removal from the body. However, as clinical experience increased, it was realised that administration of multiple doses or large doses during narcotic-based anaesthesia sometimes led to delayed recovery and prolonged respiratory depression, suggesting that the duration of action was limited by redistribution within the body rather than removal from the body. Recent developments in analytical techniques have allowed pharmacokinetic studies and these have confirmed this opinion; fentanyl is rightly regarded as having a redistribution-limited duration of action after single or infrequent doses (analogous to thiopentone). However, the magnitude of the pharmacokinetic constants reported for fentanyl are remarkably inconsistent even in healthy volunteers, for reasons apparently only explainable by assay differences. Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min. Renal excretion accounts for up to 10% of the dose; the remainder of the clearance would appear to be predominantly hepatic, but with contributions from other tissues. Continued clinical developments of narcotic-based anaesthetic techniques have resulted in high doses of narcotic being used, with oxygen, as the sole anaesthetic agents. At present these techniques are usually based on fentanyl, and the technique is frequently called 'stress-free anaesthesia' because of the effects in obtunding the 'stress response' caused by surgery (elevation of plasma concentrations of cortisol, glucose, ADH, etc. in the intra- and post-operative period) and the lack of deleterious effects on the cardiovascular system.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226471     DOI: 10.2165/00003088-198308050-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  83 in total

1.  Microelectrometric titration measurement of the pKa's and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence.

Authors:  J J Kaufman; N M Semo; W S Koski
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

Review 2.  Comparative study of cardiovascular, neurological and metabolic side effects of 8 narcotics in dogs. Pethidine, piritramide, morphine, phenoperidine, fentanyl, R 39 209, sufentanil, R 34 995. I. Comparative study on the acute toxicity and hemodynamic effects of the narcotics in high and massive doses in curarised and mechanically ventilated dogs.

Authors:  J de Castro; A Van de Water; L Wouters; R Xhonneux; R Reneman; B Kay
Journal:  Acta Anaesthesiol Belg       Date:  1979-03

3.  Continuous thoracic epidural fentanyl. A comparison of epidural fentanyl with intramuscular papaveretum for postoperative pain.

Authors:  E A Welchew; J A Thornton
Journal:  Anaesthesia       Date:  1982-03       Impact factor: 6.955

4.  The direction of opiodid agonists towards mu-, delta- and epsilon-receptors in the vas deferens of the mouse and the rat.

Authors:  M Wüster; R Schulz; A Herz
Journal:  Life Sci       Date:  1980-07-14       Impact factor: 5.037

5.  Mechanism for gastric accumulation of meperidine and effect of antacid.

Authors:  R J Trudnowski; T Gessner
Journal:  Can Anaesth Soc J       Date:  1980-09

6.  Comparative pharmacokinetics of fentanyl and alfentanil.

Authors:  S Bower; C J Hull
Journal:  Br J Anaesth       Date:  1982-08       Impact factor: 9.166

7.  Identification of fentanyl metabolites in rat urine by gas chromatography-mass spectrometry with stable-isotope tracers.

Authors:  T Goromaru; H Matsuura; T Furuta; S Baba; N Yoshimura; T Miyawaki; T Sameshima
Journal:  Drug Metab Dispos       Date:  1982 Sep-Oct       Impact factor: 3.922

8.  Gas chromatographic determination of fentanyl and its analogues in human plasma.

Authors:  T J Gillespie; A J Gandolfi; R M Maiorino; R W Vaughan
Journal:  J Anal Toxicol       Date:  1981 May-Jun       Impact factor: 3.367

9.  Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis.

Authors:  J P Haberer; P Schoeffler; E Couderc; P Duvaldestin
Journal:  Br J Anaesth       Date:  1982-12       Impact factor: 9.166

10.  A study of pethidine kinetics and analgesia in women in labour following intravenous, intramuscular and epidural administration.

Authors:  R P Husemeyer; A J Cummings; J R Rosankiewicz; H T Davenport
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

View more
  79 in total

Review 1.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

2.  Influence of age on the pharmacokinetics of alfentanil. Gender dependence.

Authors:  H J Lemmens; A G Burm; P J Hennis; M P Gladines; J G Bovill
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.

Authors:  Yoshiyuki Hoya; Tomoyoshi Okamoto; Katsuhiko Yanaga
Journal:  Support Care Cancer       Date:  2010-03-31       Impact factor: 3.603

Review 4.  Bioequivalence criteria for transdermal fentanyl generics: do these need a relook?

Authors:  Carmen Walter; Lisa Felden; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery.

Authors:  Ahmad H Malkawi; Abeer M Al-Ghananeem; Peter A Crooks
Journal:  AAPS J       Date:  2008-05-06       Impact factor: 4.009

Review 6.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

7.  Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy.

Authors:  R Tempelhoff; P A Modica; E L Spitznagel
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

Review 8.  Non-invasive methods to study drug disposition: positron emission tomography. Detection and quantification of brain receptors in man.

Authors:  B Sadzot; G Franck
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 9.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

10.  A physiologically-based recirculatory meta-model for nasal fentanyl in man.

Authors:  Richard N Upton; David J R Foster; Lona L Christrup; Ola Dale; Kristin Moksnes; Lars Popper
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-19       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.